Clinical trials: Trailing Phenomenon
Systemic Lupus Erythematosus
Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients
This study will assess the effect of a 24-week withdrawal followed by a 28-week reintroduction of belimumab 10 mg/kg plus standard of care medications in subjects with stable low systemic lupus erythematosus (SLE) disease…
- Trial name
- NCT02119156
- Testing
- Belimumab
- Where
- 20 sites in United States, China and 2 more
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline